ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
Lorenzo FerrandoAndrea VingianiAnna GarutiClaudio VernieriAntonino BelfioreLuca AgnelliGianpaolo DagradaDiana IvanoiuGiuseppina BonizziElisabetta MunzoneLuana LippolisMartina DameriFrancesco RaveraMarco ColleoniGiuseppe VialeLuca MagnaniAlberto BallestreroGabriele ZoppoliGiancarlo PruneriPublished in: PLoS genetics (2023)
ESR1 amplification and activating MAP3K mutations are potential drivers of acquired resistance to adjuvant ETs employing estrogen deprivation in HR+ HER2- BC. MAP3K mutations are associated with worse prognosis in patients with metastatic disease.